Pipeline not specifically named

About Humanwell Pharmaceutical

Humanwell Pharmaceutical US is the American R&D arm of China's Yichang Humanwell, established in 2015 to expand its parent company's legacy in anesthesia and analgesia into novel drug development. The company employs advanced computational simulation, AI/ML, and differentiated drug delivery platforms to discover and develop new chemical entities (NCEs), 505(b)(2) products, and complex generics, primarily targeting hospital/ICU care, CNS disorders, and oncology. While currently an R&D organization, it benefits from the commercial success and manufacturing scale of its publicly-traded parent company, positioning it to address significant market opportunities in pain management and complex therapeutics.

About Anodyne Nanotech

Anodyne Nanotech is pioneering a transdermal delivery platform, the HeroPatch, designed to deliver large-molecule therapeutics such as biologics and peptides without needles. Founded in 2019, the company is targeting high-value chronic conditions like obesity and sarcopenia, aiming to improve patient convenience, reduce costs, and enable new therapeutic formulations. With a seasoned leadership team and a clinical-stage pipeline, Anodyne is positioning itself as a potential disruptor in the drug delivery space through both internal development and strategic partnerships.

Therapeutic Areas